key: cord-0686667-wipk78kk
authors: Kellum, John A.; Nadim, Mitra K.; Forni, Lui G.
title: Sepsis-Associated Acute Kidney Injury: Is COVID-19 different?
date: 2020-09-10
journal: Kidney Int
DOI: 10.1016/j.kint.2020.08.009
sha: d42a75828ec4280a00e8e9608adadcd9d9f43b03
doc_id: 686667
cord_uid: wipk78kk

nan

Faced with a new disease, clinicians understandably resort to what they know. For example, we know severe viral pneumonia secondary to influenza, so when we began seeing COVID-19, our first impression was that it was a similar disease, so we felt we knew how to manage it.

However, it soon became clear that COVID-19 was strikingly different. First, there was the high transmission rate including spread within hospitals and health care workers 1 -but this could simply have been due to a new disease in a naïve population. After all, influenza is also quite contagious. Second, the numbers of patients with severe disease also seemed significantly greater, but this too could simply have been a function of the overall number of infected patients. We now know that at least 80% of patients with COVID-19 have mild or even asymptomatic disease and the majority of patients who develop critical illness with COVID-19 are over 70 years of age, suffer from underlying disease or both. Still, we are seeing cases of severe COVID-19 across all age groups and occasionally in the previously healthy. Overall casefatality rates from COVID-19 have ranged from 1-10%, making it much worse than seasonal influenza but not nearly as deadly as the two other novel beta-corona virus infections from the past-Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).

However, other distinctions between COVID-19 and diseases that we are more familiar with also began to emerge. COVID-19 can cause severe hypoxemia in patients who do not appear to be that "sick" and, although fulfilling the Berlin criteria for acute respiratory disease syndrome (ARDS), they often did not behave in a way that we expected from our "usual" practice. 2 Anecdotal reports from emergency responders in hard-hit cities featured dramatic themes such as progression from "talking to unconscious" in minutes and intensive care physicians finding themselves with patients who were profoundly hypoxemic without otherwise altered vital signs-features that are not part of severe bacterial pneumonia and equally unusual with other pathogens. The lack of shock (as measured by lower blood pressure or arterial lactate) in the majority of patients may also have contributed to the sense that COVID-19 isn't like other Finally, early reports of severe, even fatal, COVID-19 stated that kidney injury was absent. 3 This was surprising because extrapulmonary manifestations of COVID-19 appeared to be rather broad with involvement of the heart, brain and GI tract. 1, 4 Furthermore, these early reports showed evidence of systemic inflammation reminiscent of sepsis and the multi-organ failure followed this familiar pattern. While the news media embraced the term cytokine storm, reports from China suggested a "drizzle" at best. 4 However, cytokine assays are notorious for not being standardized and results from one assay system are not comparable to another.

Conversely, standardized lab tests for C-reactive protein and ferritin clearly showed severe inflammation in the sickest patients. 4 Thus, a hyperinflammatory syndrome, like the hypercoagulation, appears to be very much a part of severe COVID-19. This finding made the absence of acute kidney injury (AKI) all the more remarkable-if only it were true. By late

March it became apparent that AKI was very much a feature of severe COVID-19 and by mid-April news media in the U.S. were calling the associated renal failure a "second surge".

Much of the contradictory information on AKI in COVID-19 came from the rapid, and often unreliable, reporting as investigators raced to be the first to report their findings and journals competed to be the first to publish. Amidst this frenzy, much was overlooked and "secondary outcomes" such as AKI were not rigorously tracked. As the dust began to settle, more exacting reports specifically on AKI emerged and the findings were at the same time sobering and predictable. Overall AKI occurs in about 25-35% of patients admitted to hospital with COVID-19, nearly twice that if admitted to ICU. 5 These results are completely consistent with the published literature on bacterial pneumonia 6 and as such we might reasonably ask two related questions: 1) how different is AKI in the setting of COVID-19 than in other forms of sepsis? And, 2) how applicable is the evidence from non-COVID sepsis-associated AKI to AKI in patients with COVID-

We believe that it is important to ask both questions because if we ignore the first, the only way to answer the second is to test each and every recommendation specifically in patients with COVID-19. For example, if we recommend caution in the use of vancomycin for patients J o u r n a l P r e -p r o o f with bacterial sepsis, can we recommend the same caution in treating patients with COVID-19?

We believe that we can because vancomycin is frequently prescribed and because there is no evidence to suggest that patients with COVID-19 are less susceptible to its toxicity. Importantly, we use the term COVID-19 sepsis because many patients with severe COVID-19 meet the diagnostic criteria for sepsis and many of these develop AKI in the same way as do patients with bacterial sepsis. However, there are important differences between sepsisassociated AKI in COVID-19 compared to bacterial infection, (Table 1 ) which may directly impact how we apply evidence across the two syndromes. Nevertheless, the answer to question 1, (how different is AKI in the setting of COVID-19 than in other forms of sepsis?) would appear to be "not very different." So it follows that most, if not all, our recommendations for management of sepsis-associated AKI should also apply to COVID-19 associated AKI. 7, 8 Importantly though, all of the uncertainty we have about management of sepsis-associated AKI, like AKI in general, is also applicable. For example, we do not know precisely when to initiate extracorporeal kidney support or, even more controversially, if and when to use other forms of blood purification therapy. We also don't know exactly how to manage various tradeoffs between potentially nephrotoxic therapies (e.g. drugs, procedures) and the risks of not providing these therapies. In bacterial sepsis, these generally relate to nephrotoxic antibiotics and contrast agents for imaging. In COVID-19, we might also add the use of diuretics to reduce lung edema but possibly potentiating other nephrotoxic effects of drugs or indeed the disease itself. Finally, there are specific questions for COVID-19-what effect, if any, will low-dose corticosteroids and anticoagulation have on AKI and will any antivirals offer any protection from direct viral tropism in the kidney? In the meantime, though, our standard approach to sepsisassociated AKI, which includes careful fluid and hemodynamic management, avoidance (or cautious use) of potentially nephrotoxic agents and personalized application of extracorporeal kidney support 9 should be followed. We should not forget what we know about AKI, this common complication, even as it arises in a disease we know relatively little about. 

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China

COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med

Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Acute kidney injury in patients hospitalized with COVID

Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival

Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO clinical practice guildeline for acute kidney injury

COVID-19 Acute Kidney Injury

Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int